Degarelix

Evidence Level: L5

Predicted Indications: 10

Degarelix

Pharmacist Assessment Report

Degarelix: From Prostate Cancer to hypertrichosis (disease)

One-Sentence Summary

Degarelix is a GnRH receptor antagonist marketed in India as an injectable. The data compiled for this report do not list an approved indication text for it. The TxGNN model predicts it may be effective for hypertrichosis, but there are 0 clinical trials and 0 publications supporting this prediction, so it is a model-only signal.

Quick Overview

Item	Content
Original Indication	Not stated in the India license data (see note below)
Predicted New Indication	Hypertrichosis
TxGNN Prediction Score	0.9999
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (13 of 13) – CDSCO approval status is not included in this data
Number of Listed Products	13 (valid: 13)
Recommended Decision	Hold

Note: the license records contain no approved-indication text. Degarelix is generally known as a GnRH antagonist used in androgen-deprivation therapy for advanced prostate cancer, but this is background knowledge and is not confirmed by the data compiled for this report.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, degarelix is a GnRH receptor antagonist. It suppresses LH and FSH and thereby lowers gonadal androgen production.

The link to hypertrichosis is weak. Hypertrichosis is generally non-androgen-dependent hair overgrowth, so suppressing androgens has no clear mechanistic rationale. The very high TxGNN score (0.9999) comes from the TxGNN model (deep learning) and is not backed by any clinical or literature evidence. It may reflect similarities the model learned between related diseases, not biological evidence.

The other top predictions share this problem. Most are hair, congenital malformation or urticaria conditions with no plausible GnRH link. Two reproductive endocrine candidates are more biologically adjacent:

Central precocious puberty (score 0.9967): GnRH-dependent, so antagonism is mechanistically plausible. However, GnRH agonists are already the standard of care, degarelix is unstudied in children, and there is no evidence in the data.
Familial male-limited precocious puberty (score 0.9984): caused by activating LHCGR mutations that act independent of GnRH, so efficacy is doubtful.

These two are flagged as research questions rather than holds.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Thirteen valid single-ingredient registrations exist. The main ones are listed below. No approved-indication text is recorded for any of them.

Authorization Number	Product Name	Dosage Form	Manufacturer
85113	Firmagon 120mg Injection	Vial of 1 injection	Ferring Pharmaceuticals
84652	Firmagon 80mg Injection	Vial of 1 injection	Ferring Pharmaceuticals
63578	Degrinta 120mg Injection	Vial of 1 injection	Intas Pharmaceuticals Ltd
60011	Degapride 80mg Injection	Vial of 1 injection	Sun Pharmaceutical Industries Ltd
61482	Deghor 120 Injection	Vial of 1 injection	Glenmark Pharmaceuticals Ltd

Cytotoxicity

Item	Content
Cytotoxicity Classification	Hormonal therapy (GnRH antagonist), not a conventional cytotoxic
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Contraindications (not label text): long QT syndrome, familial long QT syndrome, torsades de pointes, liver disease, gallbladder disease, potassium deficiency disease.
Drug Interactions: 217 interactions were found in total. The 20 retrieved include:
- Major: cisapride and dolasetron, both relevant to QT prolongation.
- Moderate: clarithromycin, levofloxacin, ondansetron, granisetron, palonosetron, famotidine, loperamide, and several laxatives and bowel-preparation agents (bisacodyl, picosulfuric acid, polyethylene glycol with electrolytes, lactulose, lactitol, magnesium citrate, magnesium hydroxide, castor oil, glycerin, mineral oil).
- Minor: metronidazole.
Hypersensitivity: injection-site reactions and rare hypersensitivity are known with degarelix. This argues for caution in allergic conditions such as urticaria.

Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All ten predictions are supported only by the TxGNN model (deep learning) score, with no clinical trials or literature. Most have no plausible mechanistic link to GnRH antagonism. Central precocious puberty is the only biologically plausible candidate, and it already has an established GnRH agonist standard of care.

To proceed, the following is needed:

Package insert warnings and contraindications from the India Pharma source (a blocking gap for safety screening)
Mechanism of action data from DrugBank
Approved indication text for the India registrations, to confirm the original indication
For central precocious puberty, a focused literature and trial search, plus an assessment of pediatric safety and of advantages over GnRH agonists
A QT-risk review, given the knowledge-graph contraindication signals and the major QT-related interactions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.